Cardiff Oncology posts smaller-than-expected Q3 loss

Cardiff Oncology

06/11/2025 22:10

Overview

Cardiff Oncology Q3 net loss is smaller-than-expectations, reflecting better operational performance

Company's Q3 operating expenses decreased due to reduced clinical trial expenses

Cardiff maintains cash runway into Q1 2027, with $60.6 mln in cash and investments

Result Drivers

POSITIVE TRIAL DATA - Phase 2 trial of onvansertib shows 19% improvement in ORR for 30mg cohort vs standard care

TRIAL TOLERABILITY - Onvansertib continues to be well-tolerated with no major toxicities

COMMERCIAL OPPORTUNITY - Onvansertib positioned to address significant medical need with 150,000 new CRC patients annually in the U.S.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Royalty Revenue
$120,000
Q3 Net Income
Beat
-$11.26 mln
-$13.70 mln (8 Analysts)
Q3 Income from Operations
Beat
-$11.97 mln
-$14.30 mln (8 Analysts)
Q3 Basic EPS
-$0.17
Q3 Operating Expenses
$12.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cardiff Oncology Inc is $10.00, about 77.6% above its November 5 closing price of $2.24

Press Release: ID:nGNXccQw8D

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)